9/24 Early, Late
et al., EP Europace, doi:10.1093/europace/euaa216
(Peer Reviewed) (not included in the study count)
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.Arrhythmic safety data from a large cohort of patients treated with HCQ alone or in combination with other QT-prolonging drugs.
Gasperetti et al., 9/24/2020, peer-reviewed, 23 authors.
